These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 23489175)

  • 1. Safety assessment of subconjunctivally implanted devices containing latanoprost in Dutch-belted rabbits.
    Jessen BA; Shiue MH; Kaur H; Miller P; Leedle R; Guo H; Evans M
    J Ocul Pharmacol Ther; 2013; 29(6):574-85. PubMed ID: 23489175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of latanoprost-loaded biodegradable nanosheet as a new drug delivery system for glaucoma.
    Kashiwagi K; Ito K; Haniuda H; Ohtsubo S; Takeoka S
    Invest Ophthalmol Vis Sci; 2013 Aug; 54(8):5629-37. PubMed ID: 23868986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biodegradable nanoparticles for controlled subconjunctival delivery of latanoprost acid: in vitro and in vivo evaluation. Preliminary results.
    Giarmoukakis A; Labiris G; Sideroudi H; Tsimali Z; Koutsospyrou N; Avgoustakis K; Kozobolis V
    Exp Eye Res; 2013 Jul; 112():29-36. PubMed ID: 23603320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension.
    Olander K; Zimmerman TJ; Downes N; Schoenfelder J;
    Clin Ther; 2004 Oct; 26(10):1619-29. PubMed ID: 15598478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of a preservative-free latanoprost cationic emulsion (Catioprost) and a BAK-preserved latanoprost solution in animal models.
    Daull P; Buggage R; Lambert G; Faure MO; Serle J; Wang RF; Garrigue JS
    J Ocul Pharmacol Ther; 2012 Oct; 28(5):515-23. PubMed ID: 22671995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
    Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K
    J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
    Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A
    Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
    Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
    Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of latanoprost and brimonidine on rabbit subconjunctival fibroblasts.
    Lark KK; Pasha AS; Yan X; Edward DP
    J Glaucoma; 1999 Feb; 8(1):72-6. PubMed ID: 10084277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of latanoprost and timolol in pediatric glaucoma: a phase 3, 12-week, randomized, double-masked multicenter study.
    Maeda-Chubachi T; Chi-Burris K; Simons BD; Freedman SF; Khaw PT; Wirostko B; Yan E;
    Ophthalmology; 2011 Oct; 118(10):2014-21. PubMed ID: 21680022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye.
    Natarajan JV; Ang M; Darwitan A; Chattopadhyay S; Wong TT; Venkatraman SS
    Int J Nanomedicine; 2012; 7():123-31. PubMed ID: 22275828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models.
    Krauss AH; Impagnatiello F; Toris CB; Gale DC; Prasanna G; Borghi V; Chiroli V; Chong WK; Carreiro ST; Ongini E
    Exp Eye Res; 2011 Sep; 93(3):250-5. PubMed ID: 21396362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study.
    Higginbotham EJ; Olander KW; Kim EE; Grunden JW; Kwok KK; Tressler CS;
    Arch Ophthalmol; 2010 Feb; 128(2):165-72. PubMed ID: 20142538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of switching from topical latanoprost to bimatoprost in patients with normal-tension glaucoma.
    Sato S; Hirooka K; Baba T; Mizote M; Fujimura T; Tenkumo K; Ueda H; Shiraga F
    J Ocul Pharmacol Ther; 2011 Oct; 27(5):499-502. PubMed ID: 21790301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of 0.005% latanoprost once daily on intraocular pressure in glaucomatous patients not adequately controlled by beta-blockers twice daily: a 3-year follow-up. Experience and incidence of side effects in a prospective study on 76 patients.
    Costagliola C; Del Prete A; Verolino M; Antinozzi P; Fusco R; Parmeggiani F; Mastropasqua L
    Graefes Arch Clin Exp Ophthalmol; 2002 May; 240(5):379-86. PubMed ID: 12073061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraocular pressure control among patients transitioned from latanoprost to travoprost at a Veterans Affairs Medical Center Eye Clinic.
    McKinley SH; Singh R; Chang PT; Gross RL; Orengo-Nania S
    J Ocul Pharmacol Ther; 2009 Apr; 25(2):153-7. PubMed ID: 19284329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of 0.005% latanoprost solution on intraocular pressure in healthy dogs and cats.
    Studer ME; Martin CL; Stiles J
    Am J Vet Res; 2000 Oct; 61(10):1220-4. PubMed ID: 11039551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative, placebo-controlled study of prostanoid fluoroprostaglandin-receptor agonists tafluprost and latanoprost in healthy males.
    Sutton A; Gilvarry A; Ropo A
    J Ocul Pharmacol Ther; 2007 Aug; 23(4):359-65. PubMed ID: 17803434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension.
    Schachar RA; Raber S; Courtney R; Zhang M
    Curr Eye Res; 2011 Sep; 36(9):809-17. PubMed ID: 21851167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.